Mutations and expression of the ras family genes in leukemias

Stem Cells
D M GougopoulouD A Spandidos

Abstract

The levels of expression and the incidence of codon 12 point mutations of the ras family genes were studied in 18 cases of leukemia, seven with acute myeloblastic leukemia (AML), three with acute lymphoblastic leukemia (ALL), four cases with chronic myelogenic leukemia (CML) and four cases with chronic lymphocytic leukemia (CLL). Elevated expression of the ras genes was found for 39%, 61% and 67% of the specimens for the H-ras, K-ras and N-ras, respectively. A trend was found between the overexpression of the N-ras gene and the acute leukemias: all 10 acute leukemias exhibited overexpression of the N-ras gene, while only two of the CML cases, both in blastic crisis, showed elevated levels of the N-ras gene. Codon 12 point mutations at the N-ras gene were found in two of seven cases (28%) with AML and one of four cases (25%) with CML. The only K-ras codon 12 point mutation was found in a patient with CLL. No mutations were found in the codon 12 of H-ras. Our data suggest that apart from the point mutations, overexpression of the ras family genes is important in the development of the disease.

References

Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A NeriR Dalla-Favera
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J W JanssenC R Bartram
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C J FarrC J Marshall
Jun 2, 1988·The New England Journal of Medicine·D M LaytonC R Bartram
Aug 1, 1986·Bioscience Reports·D A Spandidos
Mar 10, 1995·Science·P H Duesberg
Dec 30, 1994·Biochimica Et Biophysica Acta·G J Pronk, J L Bos
Mar 10, 1995·Science·D Stéhelin
Mar 1, 1995·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·J VachtenheimH Roubková

❮ Previous
Next ❯

Citations

Jul 1, 1997·Critical Reviews in Oncology/hematology·G Zachos, D A Spandidos
Aug 3, 2007·Cancer Research·Chaitali ParikhRuibao Ren
May 17, 2012·Cancer Research·Ian A PriorCarla Mattos
Apr 19, 2012·PloS One·Oshrat Hershkovitz RokahOfer Shpilberg
Jan 16, 2014·Journal of Clinical Biochemistry and Nutrition·Masao YamasakiKazuo Nishiyama
Apr 17, 1999·Journal of Pediatric Hematology/oncology·K J KlopfensteinF B Ruymann
Jul 16, 2014·Expert Review of Hematology·Muneera Al-Hussaini, John F DiPersio
Mar 27, 2007·Advances in Enzyme Regulation·James A McCubreyAlberto M Martelli
Oct 30, 1998·Biochemical and Biophysical Research Communications·S MiyakisD A Spandidos
Mar 6, 1998·British Journal of Haematology·J L Byrne, C J Marshall
Mar 13, 2001·Leukemia·D M O'Gorman, T G Cotter
Jun 4, 2015·Molecular Cancer Research : MCR·John C HunterKenneth D Westover

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.